MIAMI, Dec. 1, 2022
/PRNewswire/ -- COL(R) Dallas
Hack, MD, CEO of VirTech Bio, will present the advancements
of OxyBridge™, a novel Hemoglobin-Based Oxygen Carrier (HBOC)
solution for use when tissue oxygenation is required but blood is
not an option (Patent 11504417, issued 11.22.22). Dr. Hack became
CEO of VirTech Bio in March 2022. He
had previously served the company as the Director of Medical
affairs since 2017, when he discovered that VirTech had made
substantial progress in meeting the need for an HBOC after many
other companies had failed. "I believe OxyBridge is the most
advanced human-derived HBOC in development," said Dr. Hack, "And as
a Command Surgeon in Iraq and
Afghanistan and the former
Director of the US Army Combat Casualty Care Research Program
(CCCRP) I know it's the #1 medical research priority for the DoD to
deliver this life-saving platform. For civilians, too, it can help
reduce the nearly 2 million deaths per year due to blood loss."
COL(R) Hack added, "This is personal for me, after what I
experienced in Iraq and
Afghanistan. I deeply understand
how vital this science is."
VirTech Bio has previously raised seed funding of $6.7 MM which leverages $13.7 MM awarded in non-dilutive funding to date,
primarily from the DoD. With proof-of-concept studies completed,
the company has embarked on the next phase of development, cGMP
production and IND-enabling preclinical studies. The company is
seeking equity investment of $5M to
complement and accelerate product development for both the
hemorrhagic shock market and a potentially earlier approval as a
device supporting organs prior to transplant. The Florida Venture
Summit is being held in Miami
(Dec. 6 -7, 2022) and is billed as a
premier event 'Where Innovation Meets Capital™'. More information
about the summit can be found here:
https://youngstartup.com/events/fvs22. You can also learn more
about Young Startup Ventures here: https://youngstartup.com
VirTech Bio is an early-stage biotech company based in
Natick, MA. The Company has
developed a proprietary human-derived Hemoglobin-Based Oxygen
Carrier (HBOC) solution for applications including severe
blood loss and support for organs prior to transplant. Our
team of scientists, engineers and industry veterans are committed
to delivering a universal HBOC solution to fulfill significant
unmet medical needs and save lives when minutes matter. For more
information about VirTech Bio contact us at:
info@virtechbio.com.
View original
content:https://www.prnewswire.com/news-releases/virtech-bio-presenting-at-the-florida-venture-summit-dec-6-2022-301692070.html
SOURCE VirTech Bio, Inc.